Sayre Therapeutics Announces DaunoXome® (liposomal daunorubicin) Named Patient Program in India and select SAARC markets with Galen Limited, UK

Bangalore, October 08, 2016: Sayre Therapeutics today announced the establishment of a Named Patient Program for DaunoXome® (liposomal daunorubicin) for India, Sri Lanka, Bangladesh, Nepal and Pakistan, under an exclusive distribution arrangement with Galen Limited. DaunoXome® is an anti-cancer medicine (a cytotoxic agent) that belongs to a group of medicines called anthracyclines. A Named Patient Program is a mechanism through which physicians can legally and ethically prescribe drugs which are not yet approved in a specific country, in line with local country regulations.

The active substance of DaunoXome® is daunorubicin. DaunoXome® is a special formulation of daunorubicin (in liposome form), which is used to treat a type of cancer known as Kaposi’s sarcoma. Kaposi’s sarcoma is a form of cancer that mainly affects the skin, but which can also affect the lungs and intestines. DaunoXome® reduces the growth of these tumour cells. DaunoXome® is used for the treatment of a severe form of Kaposi’s sarcoma in patients with AIDS.

A Sayre Therapeutics company spokesperson stated, “We are committed to improving patient access to liposomal daunorubicin in a legal and ethical manner. Our agreement with Galen provides a valuable resource for healthcare professionals and patients who are unsatisfied with their current approved treatment options to access liposomal daunorubicin on a named-patient basis.”

David Bennett, Managing Director of Galen Limited, stated, “We are delighted to have established this partnership with Sayre Therapeutics for India and the SAARC countries. This agreement provides an important additional option for clinicians in these countries, who are treating patients with advanced HIV-related Kaposi’s sarcoma.”

Sayre cannot respond to direct enquiries from patients. If you are a patient, or relative of a patient, looking for information regarding the availability of liposomal daunorubicin in India, Sri Lanka, Nepal, Bangladesh or Pakistan, please discuss with your physician or refer your physician directly to Sayre Therapeutics.

Physicians may contact Sayre via telephone on +91 (80) 4113 7692, fax +91 (80) 25525522, or via email at info@sayretherapeutics.com.

Corporate Comm India(CCI Newswire)